Ophthalmic Products Sample Clauses

Ophthalmic Products. Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. Confidential Treatment Requested by Homology Medicines, Inc.
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
Ophthalmic Products. In conjunction with the Royalty Reports, NVS will notify HMI [***] after the end of each Calendar Quarter in which the date on which NVS’, its Affiliates’, and its Sublicensees’ cumulative Net Sales of all Ophthalmic Products for a Target in a given Calendar Year first reach the respective thresholds indicated below in Table 11.5.1 below (each, an “Ophthalmic Sales Milestone Event”). Upon receipt of such notice, HMI shall submit an invoice to NVS substantially in the form of Exhibit A for the corresponding one-time milestone payments set forth below in Table 11.5.1 (each, an “Ophthalmic Sales Milestone Payment”). NVS will pay to HMI the corresponding Ophthalmic Sales Milestone Payment no later than [***] after receipt of such invoice.
Sample 1Sample 2Sample 3See All (4)
Ophthalmic Products. ALNYLAM: The ALNYLAM duplexes numbered [**], inclusive. MERCK: None. SCHEDULE 5.5 U.S. CO-PROMOTION AGREEMENT TERMS Commercialization: - ALNYLAM shall co-promote the Profit-Sharing Product in the United States by [**]. The costs of ALNYLAM's co-promotion efforts (consistent with the Commercialization Plan) shall be included in Commercialization Expenses for purposes of calculating U.S. Operating Profit/Loss. - ALNYLAM shall [**] to support such Profit-Sharing Product in the United States as set forth in the definitive Co-Promotion Agreement relating to such Profit-Sharing Product that is executed by the Parties pursuant to Section 5.5 of this Agreement. In the event that [**] at the time of launch of such Profit-Sharing Product in the United States, the Parties[**] following the launch of such Profit-Sharing Product in the United States. MERCK will [**], ALNYLAM shall [**]. - ALNYLAM's U.S. Co-Promotion activity shall be fully integrated into MERCK's U.S. promotion effort for such Profit-Sharing Product. - The Co-Promotion Agreement will also contain, without limitation, provisions with respect to the following matters: [**]. SCHEDULE 10 EXCEPTIONS TO REPRESENTATIONS AND WARRANTIES
Sample 1

Related to Ophthalmic Products

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

  • Competing Products The provisions of Section 21 are set forth on attached Exhibit H and are incorporated in this Section 21 by this reference.

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.

  • Product The term “

  • Combination Products If a LICENSED PRODUCT is sold to any third party in combination with other products, devices, components or materials that are capable of being sold separately and are not subject to royalties hereunder (“OTHER PRODUCTS,” with the combination of products being referred to as “COMBINATION PRODUCTS” and the Other Product and Licensed Product in such Combination Product being referred to as the “COMPONENTS”), the NET SALES of such LICENSED PRODUCT included in such COMBINATION PRODUCT shall be calculated by multiplying the NET SALES of the COMBINATION PRODUCT by the fraction A/(A+B), where A is the average NET SALES price of such LICENSED PRODUCT in the relevant country, as sold separately, and B is the total average NET SALES price of all OTHER PRODUCTS in the COMBINATION PRODUCT in the relevant country, as sold separately. If, in any country, any COMPONENT is not sold separately, NET SALES for royalty determination shall be determined by the formula [C / (C+D)], where C is the aggregate average fully absorbed cost of the Licensed Product components during the prior Royalty Period and D is the aggregate average fully absorbed cost of the other essential functional components during the prior Royalty Period, with such costs being determined in accordance with generally accepted accounting principles. To the extent that any SUBLICENSE INCOME relates to a COMBINATION PRODUCT or is otherwise calculated based on the value of one or more licenses or intellectual property rights held by the COMPANY, an AFFILIATE or SUBLICENSEE, COMPANY shall determine in good faith and report to THE PARTIES the share of such payments reasonably attributable to COMPANY’s or such AFFILIATE’s sublicense of the rights granted hereunder, based upon their relative importance and proprietary protection, which portion shall be the SUBLICENSE INCOME. THE PARTIES shall have the right to dispute such sharing determination in accordance with the dispute provisions of the AGREEMENT.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Products 1.1. The information (including but not limited to the quantity, rated hashrate, unit price (“Unit Price”), total price for one item (“Total Price (One Item)”), total price for all the items (“Total Purchase Price”) of Products to be purchased by Party B from Party A is as follows (“Products”):

  • Licensed Territory Worldwide NIH Patent License Agreement—Exclusive APPENDIX C – ROYALTIES Royalties:

  • Manufacture (a) Manufacturer shall only manufacture the specific number of Products as requested by Company and at no time shall manufacture excess goods or overruns. Manufacturer shall not sell any Products bearing the Trademarks to any third parties without the express written consent of Company.

Time is Money Join Law Insider Premium to draft better contracts faster.